What Defined 2025 for Re-Vana?

Pharmaceutical Executive: As you look back on 2025, what defined the year for Re-Vana?

Micheal O’Rourke: We've built the team. We've grown the team. We're about to expand facilities by going into we're tripling our lab space, but going into a new facility in January.

So that's taken a lot of preparation for this year. So we're really seeing this fantastic, I think growth of Re-Vana that really started off as an academic spinner company back in 2017 but I would say that 2024-2025 to your question, is really a year we can say we've really established ourselves now as a biotech company, and that's it's not easy to do that takes quite an amount of effort and time, but I would say that we have now established that with the capabilities of the team, with the proof of concept that we've chosen with. Their ability to take therapeutics from, you know, from a wide range of companies, and to encompass, encompass those into our technology and to demonstrate good proof of concept and delivery.

So it's really been, in fact, we were just looking at highlights slide for the year here, and they sort of ran out of space. Because really feel that this has been a fantastic year for Re-Vana. We've been able to expand our team. We all our employees and our industry experience. But in the world of startups, the startup has to be like a drug, right? You have to be addicted to it. So, we've now got a team that really get the passion and the dedication to understand what it's like working truly in a startup company. And we're very fortunate. You know, we've got fantastic, fantastic team members. Our Chief Operating Officer, Patrick O’Ruane our new Chief Business Officer, Hans Christinger, years of experience in this field, coupled with our scientific team here.

So that has really been a fantastic milestone for us to reach the Boehringer deal, the expansion of the team, a substantial proof of concept across additional therapeutics really has allowed Re-Vana to stand out in amongst the world of companies that are taking on board the challenges of trying how to deliver biologics, and I really feel that we have been able to crack that this year.